Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

SBB invests in newly constructed social infrastructure in the Greater Stockholm region with a WAULT of 13 years

Samhällsbyggnadsbolaget i Norden AB (publ) (“SBB”) acquires a portfolio of newly constructed educational properties in Greater Stockholm from Turako for an agreed property value of SEK 283 million. The properties with 6,942 sqm lettable area comprise of three properties containing premises for both preschool and elementary school are located in the municipalities of Nacka and Huddinge. The tenants are leading private publicly funded welfare providers. Estimated annual NOI is SEK 14.1 million and the WAULT is 13 years. “The Stockholm region is one of Europe's strongest regions, where

Announcement Re: Possible Offer for Deltic Energy

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE")  THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THE INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN FOR THE PURPOSES OF MAR.   For immediate release  5 October 2020

Photocure announces new Cevira patent in Europe

Oslo, Norway, 5 October 2020: Photocure ASA (OSE:PHO) today announces that the European Patent Office (EPO) has granted patent EP 2983780 covering the commercial Cevira[®] device in Europe until 2034.Cevira is a photodynamic drug-device combination product under development for non-surgical treatment of high-grade cervical dysplasia. In July 2019, Photocure announced that it had entered into a License Agreement providing Asieris Meditech Co., Ltd (Asieris) with a world-wide license to develop and commercialize Cevira for the treatment of HPV induced cervical precancerous lesions. In July

HEXPOL expects to report third quarter operating profit well above market expectations

HEXPOL expects to report adjusted operating profit for third quarter 2020 well above market expectations while sales are estimated to be in line with expectations. The adjusted operating profit for third quarter 2020 is expected to be in the range of 560 and 590 MSEK (583) affected by higher volumes compared to the previous quarter combined with substantially lower costs. There are no benefits related to Covid-19 Swedish government grants recorded in this result. All figures presented in this press release are preliminary and unaudited. HEXPOL will not make any further comments until

Nordic Paper intends to list on Nasdaq Stockholm

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.For complete press release, please refer to the link: https://www.nordic-paper.com/investors/ipo-confirm   For further information, please contact: Anita Sjölander, CEO of Nordic Paper Holding AB (publ)Tel:

Exchange rates for the third quarter of 2020

The net foreign exchange impact of the Kindred Group’s main trading currencies against its reporting currency of GBP is shown in the tables below. While this has no material impact on the underlying development of the Kindred Group’s business, it does affect the reported results when translated into GBP. The weighted average impact of GBP against the Kindred Group’s main currencies was a negative impact on Gross winnings revenue of less than 1 per cent in the third quarter of 2020 compared to the same period of 2019. Balance sheet rates:          Rate to GBP

Aker Offshore Wind Celebrates Successful Installation of LiDARs in South Korea

Aker Offshore Wind over the weekend successfully installed LiDARs offshore Ulsan, South Korea, marking a major milestone for the company’s KFWind consortium, which is working to develop an offshore floating wind park of 500 MW in the first stage.The LiDARs, or Light Detection and Ranging buoys, perform wind measurements and will stay in place for at least one year to collect data from the area. Following completion of the wind measurement data collection, KFWind aims to submit an application for an electricity business license in the second half of 2021, in accordance with the regulatory

Artificial Solutions agrees a flexible convertible notes funding program providing up to SEK 60 million to support accelerated growth

Artificial Solutions® International AB (publ) (“Artificial Solutions”) (SSME:ASAI) the leading specialist in enterprise-strength conversational AI, has entered into a convertible note agreement with Nice & Green S.A. (“N&G”) whereby convertible notes of up to SEK 60 million will be issued over a 14 month period which can be extended by Artificial Solutions. The convertible notes can be converted to shares at a 7 percent discount to the market price. The purpose is to underpin the company’s commitment to accelerate global sales growth of its conversational AI solutions. Following the recent

Artificial Solutions secures extension of existing EUR 11 million credit facility to support growth and issues warrants

Artificial Solutions® International AB (publ) (“Artificial Solutions”) (SSME:ASAI) the leading specialist in enterprise-strength conversational AI, has entered into an agreement with creditors to extend current credit facilities of EUR 11 million from March 31, 2021 to March 31, 2023. In addition, warrants were issued to the creditors, granting them the right to subscribe for EUR 5 million of new shares in Artificial Solutions before March 31, 2023, at a strike price of SEK 32 per share. The extension is intended to support the company’s continued growth.“The extension of our credit

Invent Medic Sweden AB’s product Efemia bladder support will be listed on the 15[th] of October for reimbursement in Germany.

Invent Medic Sweden AB announces that its distributor Arteriomed GmbH has received information from The National Association of Health Insurance Funds GKV that it will, from October 15 2020, include Invent Medic’s first product Efemia bladder support in the list of medicinal products of the statutory health insurance companies.By inclusion on the statutory list of medicinal products, Efemia bladder support will be listed to the pharmacies in Germany as an aid eligible for reimbursement, according to the Aids Directive of the Federal Joint Committee. - We are in active discussions with

Nustay files for bankruptcy following serious challenges of the COVID-19 crisis

Nustay A/S (“Nustay”) has today announced that as a result of the COVID-19 crisis, it will be filing for bankruptcy. The company has experienced a very significant drop in sales volume due to the continuing global travel restrictions - with sales at 5% of the volume of January and February 2020. This continued industry-wide uncertainty has also made meant that the company has been unable to secure sufficient funding to continue operations.COVID-19 crisis has continued to present difficult challenges As a result of the continuing global travel restrictions, Nustay’s Board of Directors

SOTKAMO SILVER AB HAS PUBLISHED THE ANNUAL REPORT FOR 2020

Sotkamo Silvers AB´s Annual Report for 2020 is available on the Company’s web page: https://www.silver.fi/en/investors/financial-reports/annual-reports Stockholm March 31, 2021 Sotkamo Silver AB Erkki Kuronen, CEO Contact person Erkki Kuronen, CEO, tel. +358 50 599 3539 This information is information that Sotkamo Silver AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above on March 31, 2021, at XX:XX CET. The

Scandion Oncology announces that it has been selected for the final round of MATWIN presentations

Scandion Oncology A/S (“Scandion Oncology”) today announces that the company has been selected to present the company for the MATWIN Board and investors.The MATWIN program is an activity installed by the French Government as a collaboration with Pharma companies, investors and patient advocacy groups to accelerate development of future oncology treatments. Projects selected in the MATWIN process are characterized by high quality science and a ground-breaking potential to make a difference for cancer patients. In the selection process candidate projects are on the one hand scrutinized and

Teleste has signed an agreement to sell its services business in Germany to Circet

TELESTE CORPORATION   INSIDER INFORMATION   2 October 2020 AT 22:00 EET TELESTE HAS SIGNED AN AGREEMENT TO SELL ITS SERVICES BUSINESS IN GERMANY TO CIRCET  Teleste has signed an agreement to sell its services business in Germany to Circet Deutschland GmbH, a company of the Circet Group. Circet is the leading European telecom network service provider with activities in France, Ireland, the UK, Spain, Germany and Morocco. Circet provides a wide range of construction, installation and maintenance services for fixed and mobile networks. In 2019, the revenue of Circet was EUR 1.4 billion

Communique from the Extraordinary General Meeting of Scandion Oncology A/S

On Thursday 1 October 2020, the Extraordinary General Meeting of Scandion Oncology A/S was held. Below follows a summary of the established decisions. All decisions were taken with the required majority and in accordance with the notice of the extraordinary general meeting.Establishment of an incentive program by issuance of warrants to the board of directors The general meeting decided that Scandion Oncology A/S will establish an incentive program by issuance of up to 214,338 warrants to the board of directors of Scandion Oncology A/S to be distributed as follows: (i) Chairman: 71,

Major shareholder announcement – Société Générale S.A.’s holding above 5 percent as at 30 September 2020

Vestas Wind Systems A/S, Aarhus, 02 October 2020Company announcement No. 30/2020   Major shareholder announcement – Société Générale S.A.’s holding above 5 percent as at 30 September 2020 Pursuant to Section 30 of the Danish Capital Markets Act, Vestas Wind Systems A/S hereby informs that the company has been notified on 2 October 2020 that Société Générale S.A., 29 Boulevard Haussmann, 75009 Paris, France, on 30 September 2020 had the following holding of Vestas shares and financial instruments – corresponding to a position of 5.76 percent of the total share capital in Vestas

The subscription price for the warrants of series 2020:1 has been set to SEK 12.00 and the exercise period begins on Monday 5 October 2020

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, BE SUBJECT TO LEGAL RESTRICTIONS OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES During June-July 2020, Eurobattery Minerals AB (publ) (NGM Nordic SME: "BAT"; "the Company") carried out a rights issue of units, consisting of shares and warrants of series 2020:1 (the “Warrants”). Those who

Offer document regarding Peutinger AB’s mandatory cash offer to the shareholders of Internationella Engelska Skolan i Sverige Holdings II AB (publ) made public

THIS PRESS RELEASE IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA OR SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED BY APPLICABLE LAW. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE SECTION TITLED “IMPORTANT INFORMATION” AT THE END OF THIS

Record date for distribution of warrants of series TO1 and TO2 to current shareholders is set for October 9, 2020

As previously announced, the Board of Directors of Cereno Scientific AB (”Cereno” or the ”Company”) has decided to distribute warrants of series TO1 and TO2 free of charge to shareholders in the Company. The subscription period to subscribe for new shares of series B with conversion of warrants from series TO1 will be from 15 September 2021 until and including 29 September 2021. The subscription period to subscribe for new shares of series B with conversion of warrants of TO2 will be from 14 September 2022 until and including 28 September 2022.As previously announced through a press release

UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 02.10.2020

United Bankers Corporation NOTIFICATION 02.10.2020 at 18:30 UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 02.10.2020 Date 02.10.2020Exchange transaction BuyShare class UNIAVAmount 562Average price/share 9.2000 EURHighest price/share 9.2000 EURLowest price/share 9.2000 EURTotal price 5,170.40 EUR The shares held by United Bankers Corporation on 02.10.2020: UNIAV 19,769   On behalf of United Bankers Corporation  Skandinaviska Enskilda Banken AB (Publ) Antti

Cantargia reports first patient treated with CAN04 in a US phase I study investigating combination with pembrolizumab

Cantargia AB today announced that the first patient has started treatment with the antibody CAN04 and pembrolizumab in a phase I clinical trial in USA. The trial continues according to the clinical protocol and will include up to 18 patients.Cantargia develops antibody-based pharmaceuticals against interleukin-1 receptor accessory protein (IL1RAP). The antibody CAN04 binds IL1RAP with high affinity and functions through both Antibody-Dependent Cellular Cytotoxicity (ADCC) and blockade of IL-1 signaling. A new phase Ib clinical trial investigates CAN04 in combination with pembrolizumab which

An Advocacy Toolkit for Nature: Biodiversity loss, nature protection, and the EU strategy for nature

Nature matters, because…  · Biodiversity underpins all life on Earth  · Losing biodiversity means losing the vital services that societies depend on  · Ecosystems and soils absorb carbon and help us limit the effects of climate change  The Advocacy Toolkit for Nature, published under the EU Biodiversity Strategy for 2030, offers an overall understanding of biodiversity loss and its effects in nature, the reasons behind it and the link with climate change.  Read the Advocacy toolkit in 25 languages.

Board Member Artur Aira is taking the position as Bioprinting Business Area Manager

Artur Aira, who holds a master’s degree in medical technology engineering and an MBA, is leaving the CELLINK Board of Directors for an operational role as Business Area Manager for the bioprinting business unit. Artur has a wealth of experience within the life sciences industry, has served as CEO Abigo medical, Executive Vice President at AddLife, and has held various leadership roles at Organon Teknika, bioMerieux and AddTech Life Science. With over 30 years’ experience, he is an authority on setting up organizations in the pharmaceutical and diagnostics industries to achieve impressive

HANZA invites to Q3 2020 presentation on November 3 at 11.oo am

HANZA Holding AB (publ), will publish its interim report for the third quarter of 2020 on Tuesday November 3, at 8.00 am CET. In connection with the report, HANZA invites investors, shareholders and journalists to a combined audiocast and conference call at 11.00 am CET the same day.The report will be presented by Erik Stenfors, CEO, and Lars Åkerblom, CFO.The presentation will be held in English.  Link to webcast:https://tv.streamfabriken.com/hanza-q3-2020  Dial in numbers for the conference call: Sweden: +46 8 566 427 03United Kingdom: +44 333 300 92 62USA: +1 833 249

There are no items matching the current filter
There are no more items matching the current filter
Back to top